Elsevier announces standards-ready clinical decision support enhancements in Gold Standard Drug Database to enable interoperability and transparency in healthcare applications

Elsevier announced new clinical decision support (CDS) enhancements in its Gold Standard Drug Database (GSDD) that enable customers to use industry-standard identifiers across core medication safety checks and provide transparent responses when no alert is triggered. The updates aim to help healthcare technology companies and pharmacy organizations integrate CDS faster, reduce manual exception queues, and operate confidently in multi‑vendor ecosystems.

GSDD now accepts RxNorm (RxCUIs) ICD‑10-CM, ICD-10-PCS and SNOMED CT as inputs for drug interaction, duplicate therapy and drug–disease safety checks, including contraindications and precautions. New input validation delivers explicit “reason responses” when no alert is produced, giving product and engineering teams clear, actionable insight into CDS behavior.

Elsevier is also enhancing Drug-Allergy safety checking, made available in March 2026, with support for RxCUI and SNOMED CT allergen inputs. A new allergy catalogue will be introduced to support clinician, patient, and consumer documentation, RxNorm and SNOMED CT drug substances, brands, drug classes, dietary and environmental allergens.

Rhett Alden, Chief Technology Officer at Elsevier said “These standards-ready capabilities reflect our commitment to helping customers meet interoperability requirements while improving operational efficiency. RxNorm, ICD-10, and SNOMED CT are cornerstone clinical terminologies that make interoperability possible by ensuring different systems mean the same thing when they exchange data. By utilizing these industry standard identifiers and providing transparent responses, we’re supporting safer, faster workflows without requiring our valued customers to rearchitect their systems. Transparency matters in clinical decision support – clear responses reduce unnecessary exception reviews and accelerate troubleshooting. Combined with standards-based inputs, customers can implement CDS more quickly and trust the results they see.”

The enhancements reinforce Elsevier’s clinical depth and ongoing content maintenance, aligning with the company’s broader focus on delivering safety, efficiency, and scalability across the health information ecosystem.

About Gold Standard Drug Database

Elsevier’s Gold Standard Drug Database (GSDD) provides normalized, clinically curated medication product and semantic data to help organizations standardize drug information and support medication management, clinical decision support, and interoperability across healthcare workflows. Maintained by clinical pharmacists and subject‑matter experts, GSDD integrates via flexible data feeds and APIs and is used by health systems, payers, pharmacies, and health‑technology companies.

About Elsevier

エルゼビアは、先端情報と意思決定支援の分野におけるグローバルリーダーです。1世紀以上にわたり、科学と医療の発展を通じて人類の進歩に貢献してきました。世界170か国において、学術・企業の研究コミュニティ、医師、看護師、将来の医療従事者、教育関係者の重要な活動を支援しています。エルゼビアは、世界有数のエビデンスに基づく科学・医学コンテンツ、精度の高いAI、そして専門家による評価を基盤とした研究・臨床レベルのソリューションを提供し、より良い成果の実現を支援しています。また、サービスを提供するコミュニティと連携しながら、多様性とサステナビリティの推進にも取り組んでいます。エルゼビア財団opens in new tab/window（Elsevier Foundation）は、世界各地における研究および医療分野のパートナーシップを支援しています。

エルゼビアは、専門家およびビジネス向けの情報分析および意思決定ツールを提供するグローバル企業、RELXopens in new tab/windowの一員です。詳細については、https://www.elsevier.com/ja-jp をご覧いただくか、ソーシャルメディアの @elsevierconnect をご参照ください。